Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead set to acquire Arresto for $225 million

December 23, 2010
Research and Development AB0024, Arresto, Cancer, Gilead, advanced solid tumours, ambrisentan, fibrotic diseases, idiopathic pulmonary fibrosis

Gilead Sciences is set to acquire fellow California, US-based biotech Arresto for $225 million to bolster its early stage pipeline. …

News

Service Insight: New year, new resolution and priorities for 2011

December 23, 2010
Medical Communications Jo Spadaccino, Pegasus PR, Service Insight, Talking Point

SERVICE INSIGHTNow the nights have drawn in and as Christmas music drives this writer to distraction, my attention has been …

Feature
Blog footer

Digital Pharma: FDA delays social media guidance until 2011

December 22, 2010
Medical Communications Digital Pharma blog, FDA, social media

The FDA will release its hotly-anticipated social media guidance for pharma companies in a piecemeal fashion, beginning in the first …

News

AstraZeneca takes $445m hit to halt motavizumab

December 22, 2010
Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus

AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …

News

Novartis blood cancer drug impresses in late stage trial

December 22, 2010
Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug

Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …

News

Novo to develop oral insulin

December 22, 2010
Research and Development Emisphere, Novo Nordisk, diabetes, insulin, oral insulin, type I diabetes

Novo Nordisk is to develop an oral formulation of insulin with US biotech company Emisphere Technologies. The New Jersey-based biotech …

News

BMS licences phase II HIV compound festinavir

December 22, 2010
Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor

Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …

News

Liberating the NHS … whether it likes it or not

December 22, 2010
Sales and Marketing GP consortia, NHS, NHS board, NHS reforms, value-based pricing

When health secretary Andrew Lansley announced plans in July to abolish the management structure of England’s health service, and hand …

Feature
astrazeneca_esra_erkal_paler

AstraZeneca appoints Esra Erkal Paler head of global media relations

December 22, 2010
Medical Communications AstraZeneca, Esra Erkal Paler, appointment, medical communications

AstraZeneca has appointed Esra Erkal Paler to head up its worldwide media relations activities. She will lead the company’s London-based …

Appointment

Roche to challenge FDA on Avastin

December 21, 2010
Sales and Marketing EMA, FDA, Roche, avastin, bevacizumab, breast cancer

Roche is set to challenge the decision by the FDA to remove a breast cancer indication from its blockbuster drug …

News

Novartis makes $500m investment in Russia

December 21, 2010
Manufacturing and Production, Research and Development Novartis, Russia, pharma manufacturing

Novartis is planning to invest $500 million in Russia over the next five years, in a programme which will include …

News

Pharma manufacturing news in brief

December 21, 2010
Manufacturing and Production Airgas, Anthera Pharmaceuticals, Avid Bioservices, Berlin Packaging, Continental Packaging Solutions, Inno Biologics, Janssen, Merck BioManufacturing Network, Shandong Yanggu Zhongshi Pharmaceutical, SurModics

Our round-up of manufacturing updates includes a European recall for J&J, new contract manufacturing awards and facility updates from around …

News

NHS framework outlines GP consortia assessment plans

December 21, 2010
GP consortia, NHS, NHS Commissioning Board, NHS Outcomes Framework, NHS reform

The government has published details of how the new GP-led consortia, which will commission health services in the future, will …

News

Biogen Idec buys neurodegenerative disease rights

December 21, 2010
Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases

Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

News

Congressman says FDA should scrutinise J&J’s manufacturing partners

December 21, 2010
Manufacturing and Production BestSweet, FDA, J&J, JJ, Johnson & Johnson, McNeil, Rolaids, manufacturing compliance, recalls

The latest flurry of recalls from Johnson & Johnson has prompted additional calls for a wide-ranging investigation of the company’s …

News

Scottish First Minister seeks talks with Aptuit over plant closures

December 21, 2010
Manufacturing and Production Aptuit, Scotland, manufacturing facilities, pharma manufacturing

US contract manufacturing and drug development company Aptuit says it may shut down two facilities in Lothian, Scotland, because demand …

News

CRM and software-as-a-service

December 21, 2010
Sales and Marketing CRM, Dan Goldsmith, Service Insight, Veeva Systems

Service Insight from Dan Goldsmith, general manager, Europe, Veeva SystemsCriminal mastermind, Frank Abagnale Jr. (1901-1980), successfully conned millions of dollars …

Feature

Contract research news in brief

December 20, 2010
Research and Development Biomodels, CIT, Charles River Laboratories, Dedicated Phase I, INC Research, PPD

Our round-up of recent development in the contract research sector includes updates from Charles River, CIT/Biomodels, INC Research, PPD and …

News
AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor)

FDA delays approval of AstraZeneca’s Brilinta

December 20, 2010
Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome

US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …

News

Italy OKs first large-scale unit for making radiolabelled peptides

December 20, 2010
Manufacturing and Production AIFA, Advanced Accelerator Applications, BioSynthema, Italy

The world’s first industrial-scale manufacturing facility for radiolabelled peptides used in nuclear medicine has been approved by the Italian Pharmaceutical …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026